Background: There may be discordance between tumor size determined by magnetic resonance imaging (MRI) and that observed during pathologic analyses. Purpose: To evaluate MRI-pathology concordance of tumor size in patients with invasive breast carcinoma. Material and Methods: Data from 307 invasive breast carcinomas were analyzed retrospectively. Preoperative breast MRI was reviewed for size, lesion type, morphology, and dynamic contrast-enhanced tumor kinetics. MRI tumor size was compared with tumor size measurements from the pathologic analysis. Concordance was defined as a difference in diameter of 0.5 cm. MRI-pathology concordance was compared according to clinical and histopathologic features. Results: The mean tumor size on MRI was 2.48 AE 1.41 cm. Tumor measurements determined by MRI were not significantly different from those recorded in the pathologic reports (2.56 AE 1.61 cm, P ¼ 0.199). MRI-pathology concordance was found in 229/307 (74.6%) cases; the size was overestimated in 36 (11.7%) tumors and underestimated in 42 (13.7%). On univariate analysis, MRI-pathology discordance was associated with larger tumor size (P < 0.001), estrogen receptor (ER) negativity (P ¼ 0.006), and lymphovascular invasion (P ¼ 0.003). Human epidermal growth factor receptor 2 positive molecular subtype showed worse correlation between the tumor size measured by MRI and pathology compared with luminal A and luminal B subtypes (P ¼ 0.008 and 0.007). On multivariate analysis, tumor size and ER status significantly influenced MRI-pathology concordance (P < 0.05). Conclusion: ER negativity and larger tumor size were strongly associated with MRI-pathology discordance in invasive breast carcinomas. Awareness of these factors might improve surgical planning.
Introduction
An accurate preoperative estimation of tumor size using imaging techniques is important for treatment planning and patient management (1) . Complete excision of malignant foci is the standard and can reduce tumor recurrence (2) . Recently, magnetic resonance imaging (MRI) has been increasingly used in the management of patients with breast cancer, and has been shown to be more precise than ultrasonography or mammography for estimating the local extent of breast carcinoma and detection of additional tumor foci (3) .
In breast carcinomas, the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 status of the tumor are used as biomarkers for treatment planning and subtype definitions (4) . Breast cancer patients with ER/PR positive tumors have a superior prognosis and increased treatment options compared with ER/PR negative patients, whereas HER2 expression and the Ki-67 index are prognosticators for lymph node metastasis and tumor infiltration (5, 6) .
The factors affecting discordance between MRI and histopathological tumor size measurements have been investigated previously. Mennella et al. (2) showed that ductal carcinoma in situ (DCIS) histology was strongly associated with discordance. In addition, non-mass enhancement was a significant predictor of discordance (7) . However, little is known about the influence of immunohistochemical factors on tumor sizing in invasive breast carcinoma.
The aim of this study was to investigate the factors that influence MRI-pathology concordance in tumor size in patients with invasive breast carcinoma, with emphasis on hormonal receptor status.
Material and Methods
The study protocol was approved by the Institutional Review Board at our institution (GDIRB 2016-088). All procedures were conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived because of the retrospective nature of the present study.
Patients
A retrospective analysis of the medical records of patients with surgically confirmed breast carcinoma, who were treated at our institution between January 2013 and August 2015, was conducted. A total of 582 patients underwent a breast MRI examination. Of these patients, we excluded those who underwent neoadjuvant chemotherapy, those with DCIS, those who had invasive carcinoma with an extensive intraductal component, those who underwent excisional biopsy before breast MRI, and those who did not have pathologic data such as the nuclear grade, histologic grade, and HER2 status. DCIS and invasive cancer with an extensive intraductal component were excluded because of the potentially problematic nature of determining an accurate pathologic size (8, 9) .
Further clinical information including the age, symptoms or signs (tumor palpability and nipple discharge), and familial status of breast cancer were also reviewed.
MRI protocol
MRI was performed with the patient in the prone position using a 3T machine (Skyra and Verio, Siemens Medical Solutions, Erlangen, Germany) equipped with a breast coil. The imaging protocols consisted of a fat-suppressed T1-weighted (T1W), T2-weighted (T2W), axial or sagittal, three-dimensional (3D), gradient echo sequence, and dynamic contrast-enhanced (DCE) images. Imaging using a 3T Skyra scanner covered both breasts with minimum repetition and echo times (4.79 and 1.83 ms, respectively, for the dynamic images), a 10 flip angle, a 34-cm field of view, a 1.5-mm section with no gap, a 512 Â 512 matrix, and had a scan time of 1-2 min. Imaging with the 3T Verio scanner covered both breasts with minimum repetition and echo times (4.7 and 1.78 ms, respectively, for the dynamic images), a 10 flip angle, a 35-cm field of view, a 1.5-mm section with no gap, a 512 Â 512 matrix, and had a scan time of 1-2 min. DCE-MRI was performed using axial imaging, with one pre-contrast and six postcontrast dynamic series. Image acquisition time per dynamic scan was 60-66 s. For DCE imaging, 0.1 mmol/kg body weight gadobutrol (Gadovist; Bayer Schering Pharma AG, Berlin, Germany) was injected, followed by a 20-mL saline flush. After the examination, two subtraction images were automatically produced on a pixel-by-pixel basis; the unenhanced images were subtracted from the second postcontrast images (standard subtraction), and the last postcontrast image was subtracted from the second postcontrast image (reverse subtraction). If the lesion demonstrated a kinetic pattern showing an early rise and an early washout, the lesion would be observed with the remaining high signal intensity on reverse subtraction images (10) . The reformatted images with a maximum intensity projection (MIP) were created from the standard and reverse subtraction images. We evaluated the concordance rates between MRI and pathology according to two different scanners.
Image analysis
Images were interpreted independently by two breast radiologists (YEY, NSY) with 7-8 years of experience, respectively, in breast imaging. Both reviewers were blinded to the clinical and radiologic information of all patients. Image manipulations did not involve computer-aided detection. Interpretations were performed by a consensus review to resolve any differences in opinion. MIP images were used for tumor size measurements. Tumor size was measured in the anatomical planes (transverse, sagittal, and coronal plane), which were oriented relative to the long axis of the body. If the classification of tumors on MIP images was difficult because of the presence of marked background enhancement or tumors that showed slow or continuous enhancement, tumor size was analyzed in the sequence that showed maximum contrast uptake.
Concordance between MRI and pathologic diameter was defined as a tumor size difference of 0.5 cm. This is because limits within which measurements on MRI are considered concordant with measurements at pathology vary and are in the range of 0-2 cm (3,7,11-16); however, the majority of previous studies that classified concordance defined a diameter difference of 0.5 cm as concordant. Disease was considered to be overestimated if the size of the tumor on MRI was > 0.5 cm larger than the pathologic tumor size. Conversely, disease was considered to be underestimated if the size of the tumor on MRI was > 0.5 cm smaller than the pathologic tumor size.
Tumor morphology, DCE kinetics, and multiplicity were analyzed based on the American College of Radiology Breast Imaging Reporting and Data System MRI lexicon, 2nd edition (17) . Lesions were classified as mass or non-mass enhancement lesions. The shape (oval, round, or irregular), margin (circumscribed, irregular or spiculated), and internal enhancement characteristics (homogeneous, heterogeneous, rim enhancement, dark internal septations) of a mass lesion were evaluated. The DCE kinetic time-intensity curve was assessed based on delayed phases. The delayed phase was categorized into three types: type 1, persistent; type 2, plateau; or type 3, washout. Multiplicity was defined as the presence of more than one unconnected breast lesion. When there were multiple lesions in a breast, the largest lesion alone was analyzed.
Histopathologic features
Pathological reports were reviewed for the following parameters: tumor histologic subtype, tumor size, multiplicity, Ki-67 index, lymphovascular invasion, nuclear grade, histologic grade, and ER, PR, and HER2 status. Positive ER and PR status were defined by an Allred score ! 3 based on immunohistochemical staining. HER2 status was considered positive if the Allred score was 3 þ or 2 þ with confirmation of HER2 gene amplification by silver in situ hybridization. Breast cancers were divided into four molecular subtypes, as per the recommendations of the 13th International Breast Cancer Conference held at St Gallen, Switzerland in 2013 (4), as: luminal A (ER and/or PR positive, Ki-67 20%, HER2 negative), luminal B (ER and/or PR positive, as well as Ki-67 > 20% or HER2 positive), HER2 positive (ER negative, PR negative, HER2 positive), and triple negative (ER negative, PR negative, HER2 negative).
Tumors were divided into three histologic groups: invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and ''other'' (mucinous, papillary, tubular, medullary, cribriform, apocrine, and mixed cancers).
Statistical analysis
MRI and pathology-determined tumor sizes were compared using a paired t-test and Spearman's Rho correlation analysis. Statistical analyses of the patients' age and tumor size were performed using the Student t-test and Mann-Whitney U test, respectively. Concordance rates between MRI and pathology according to MRI machine, histologic subtype, molecular subtype, lymphovascular invasion, multiplicity, MRI characteristics, and ER, PR, and HER2 status were compared using the Chi-squared test. After a positive Chi-squared test (P < 0.05), a Bonferroni post-hoc analysis was conducted performing pairwise comparison of subgroups. Multivariate logistic regression analysis was performed to determine factors influencing the accuracy of MRI. All statistical analyses were performed using SPSS software version 19.0 (SPSS Inc., Chicago, IL, USA), and P < 0.05 was considered statistically significant.
Results
A total of 307 patients were included. The mean patient age was 53.2 years (age range, 30-82 years). The molecular subtype distribution was luminal A, 28.3% (87/307); luminal B, 42.3% (130/307); HER2 positive 12.1% (37/307); and triple negative, 17.3% (53/307). Tumor histology was as follows: 251 IDC (81.8%); 16 ILC (5.2%); and other histological types included 13 mixed cancers (4.2%), ten mucinous (3.3%), five medullary (1.6%), four papillary (1.3%), three micropapillary (1.0%), two apocrine (0.7%), two cribriform (0.7%), and one tubular carcinoma (0.3%).
The mean tumor size on MRI was 2.48 AE 1.41 cm. Tumor measurements determined by MRI were not significantly different to those recorded in the pathological reports (2.56 AE 1.61 cm, P ¼ 0.199). The overall correlation between pathology and MRI measurements was strong (Spearman's rho ¼ 0.875, P < 0.001). Tumor sizes were concordant in 229/307 patients (74.6%). MRI overestimated the size of 36/307 tumors (11.7%) with a mean overestimation of 1.26 AE 0.79 cm. MRI underestimated the size of 42/307 tumors (13.7%) with a mean underestimation of -1.84 AE 1.83 cm.
Sixty-eight patients were examined using the 3T Skyra machine. Tumor sizes were concordant in 52/68 (76.5%). MRI overestimated the size of 8/68 (11.8%) tumors and underestimated the size of 8/68 (11.8%) tumors. A total of 239 patients were examined using the 3T Verio machine. Tumor sizes were concordant in 177/239 (74.1%) cases. MRI overestimated the size of 28/239 (11.7%) tumors and underestimated the size of 34/239 (14.2%) tumors. There was no significant difference in the MRI-pathology concordance between patients imaged with Skyra or Verio imagers (P ¼ 0.898).
Effect of clinicohistologic factors on the differences between MRI and pathology measurements
A comparison of the clinicohistologic characteristics affecting MRI-pathology concordance of tumor size and MRI-pathology discordance of tumor size are shown in Table 1 . MRI-pathology discordance was associated with larger tumor size on pathology (P < 0.05), lymphovascular invasion (33.2% versus 52.6%, P ¼ 0.003), and ER negativity (P ¼ 0.006). In addition, MRI-pathology concordance was significantly different between the breast cancer subtypes (P ¼ 0.019). In a post-hoc analysis, the correlation between the tumor size measured by MRI and pathology was worse for HER2-positive subtypes compared with those for luminal A and luminal B subtypes (P ¼ 0.008 and P ¼ 0.007). There were no significant differences in MRI-pathology concordance according to the histologic subtype and multiplicity on pathology.
In a multivariate logistic regression analysis, larger tumor size and ER negativity significantly influenced MRI-pathology discordance in tumor size (P < 0.001, P ¼ 0.033, Table 2 ).
The relationship between MRI features and MRIpathology concordance of tumor size Table 3 summarizes the comparison of analyzed MRI features from 229 MRI-pathology concordant patients and 78 MRI-pathology discordant patients. A total of 228 of 229 MRI-pathology concordant cancers (99.6%) showed mass lesions ( Fig. 1) and one (0.4%) showed a non-mass enhancement lesion. Sixty-nine of 78 MRIpathology discordant cancers (88%) showed mass lesions and eight (10%) showed non-mass enhancement lesions (Fig. 2) . Therefore, according to a univariate analysis, MRI-pathology discordant cancers were more likely to show non-mass enhancement (P < 0.001). In addition, non-mass enhancement significantly influenced MRI-pathology discordance when the discordant group divided into the overestimated group and the underestimated group (P < 0.001). In a post-hoc analysis, the correlation between the tumor size measured by MRI and pathology was worse for underestimated group compared with concordant group (P < 0.001). No other MRI features significantly affected the discrepancies between MRI and pathologic measurements of tumor size.
Discussion
In the present study, we examined factors influencing the MRI-pathology concordance of tumor size in invasive breast carcinomas. We found that MRI-pathology discordance of tumor size was significantly associated with ER negativity and larger tumor sizes. The preoperative performance of breast MRI for patients with newly diagnosed breast cancer increases the sensitivity of characterizing the extent of disease by improving assessment of tumor size and detection of additional tumor foci (18) . Preoperatively, tumor size is used for clinical staging and evaluation of a patient's candidacy for breast conservation and neoadjuvant chemotherapy (19) . Several studies have investigated the potential for under-or overestimation of tumor size on MRI, yielding mixed results. Leddy et al. (19) found that MRI significantly overestimated tumor size (68.4%) compared with mammography (33.3%) and ultrasonography (45.6%). In a recent study, the mean difference was 0.2 cm, which corresponded to a nonsignificant size overestimation by MRI (20) . Similarly, in the present study, tumor size determined by MRI was not significantly different to that in the pathologic reports. Onesti et al. (12) described a significant overestimation of tumor size on MRI, particularly in tumors measuring > 2.0 cm. Grimsby et al. (3) evaluated concordance between MRI and pathologic tumor size and found that MRI provided an accurate estimation of tumor size, especially in tumors 2 cm. Similarly, in the present study, MRI-pathology discordance was associated with larger tumor size.
Several studies have indicated that MRI-pathology discordancy of tumor size was more likely in non-massenhancing lesions than in mass lesions (7, 21) . We also found considerable rates of MRI-pathology discordancy for invasive breast cancers with non-mass enhancements. A possible explanation for MRI-pathology discordancy in non-mass-enhanced lesions is that it is difficult to measure the size of diffuse tumors. Diffuse tumors do not form a distinct tumor body and it is difficult to determine the borders of the tumor, even histologically (22) .
In a recent study, DCIS histology was strongly associated with discordance between MRI and pathology sizing of breast cancer tumors (2) . However, several studies have found that DCIS histology did not significantly affect MRI-pathology concordance (3, 12) . In addition, recent studies have suggested the potentially problematic nature of determining an accurate pathology size for DCIS lesions (8, 9) . Accordingly, the present analysis excluded all DCIS lesions. Breast cancers with different ER, PR, and HER2 statuses have distinct prognoses and variable responses to endocrine therapy, radiation therapy, and chemotherapy (23) (24) (25) . ER-negative breast cancers exhibit high cellular proliferation and more aggressive behavior compared with ER-positive cancers (26) . In the present study, the correlation between tumor size evaluated by MRI and pathology was weaker in ERnegative tumors. Koukourakis et al. (27) reported a strong inverse association of microvascular density with ER expression. According to the previous report, ER-negative breast cancers had several common morphological features including high-grade comedo-type necrosis, lymphoid stroma, and central necrosis/fibrosis (28). Chen et al. (29) found that ER-negative breast cancers had larger tumors at the time of diagnosis, and more frequently presented with a non-mass enhancement pattern compared with ER-positive cancers. According to Taneja et al. (30) , hormone receptor negative cancers had a higher incidence of ill-defined masses compared with hormone receptor positive cancers. These findings might explain why MRI-pathology discordancy in tumor size was associated with ER negativity in the present study.
A limitation of the present study is the retrospective study design. A large-scale, prospective study would provide more accurate findings for MRI features and would validate the present findings. Second, inter-and intra-observer variabilities remain a concern for histologic diameters measurement.
In conclusion, ER negativity and larger tumor size might influence the MRI-pathology concordance of breast tumor size measurements in breast MRI. Awareness of these factors might improve surgical planning.
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